RAS mutations and personalized cancer care: Targeting the future
touchEXPERT OPINIONS for touchONCOLOGY
Listen to a medical oncologist, a pancreatic cancer specialist and a lung cancer specialist discuss the role of RAS mutations in solid tumours, notably pancreatic cancer and NSCLC, and how they may be therapeutically targeted to improve patient outcomes.
The experts
Dr David S Hong, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Dr Eileen M O’Reilly, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA
Dr Rebecca S Heist, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.